Systematic Review: Kratom Shows Preclinical Pain Relief But Human Evidence Remains Insufficient

Why it matters

This systematic review provides the most current synthesis of kratom's analgesic evidence, confirming that while animal models are consistently positive, the human data are too limited and inconsistent to support clinical use for pain management — a key finding for clinicians and regulators weighing evidence-based policy.

The big picture

Kratom's primary alkaloid, mitragynine, differs from classical opioids by exhibiting reduced beta-arrestin recruitment at the mu-opioid receptor, which in theory could translate to fewer respiratory side effects. This pharmacological distinction has fueled interest in kratom as an alternative analgesic. However, translating preclinical promise to human clinical evidence has proven difficult, with most human studies being small, short-term, and conducted in healthy volunteers rather than pain patients.

Key findings

• Researchers conducted a systematic search across PubMed, ScienceDirect, Cochrane Library, Springer, Scopus and Google Scholar, identifying 44 eligible studies: 28 preclinical and 16 human.
• Preclinical data consistently showed dose-dependent antinociceptive and anti-inflammatory effects across acute, inflammatory, and neuropathic pain models.
• In human studies, mitragynine did not significantly alter pain threshold or tolerance; kratom decoction modestly increased pain tolerance in a single experimental pain paradigm in healthy volunteers.
• About 19.3% of human subjects reported adverse effects (another 12.8% reported possible adverse effects); most were mild and resolved within one day.
• Long-term safety data are lacking; chronic or high-dose use may carry dependence, withdrawal, and CYP3A4/CYP2D6-mediated drug interaction risks.

What they say

The authors concluded: "The current evidence is insufficient to support the clinical efficacy of kratom for pain management. While short-term exposure appears generally well tolerated, long-term safety data are lacking, and chronic or high-dose use may be associated with dependence or withdrawal risk."

Bottom line

**A 44-study systematic review confirms kratom has consistent pain-relieving effects in animals but insufficient human evidence to support clinical use — and flags ongoing concerns about dependence and drug interactions.**